RCT | Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial – JAMA Dermatology

Commentary: Tralokinumab Efficacious, Well-Tolerated for Adolescents with Atopic Dermatitis – HCP Live

Commentary on Twitter

The ECZTRA 6 trial showed that targeted IL-13 inhibition with tralokinumab was efficacious and well tolerated in adolescents with moderate-to-severe AD, suggesting that it is a valuable treatment option in this age group. https://t.co/h36BW4XThE

— JAMA Dermatology (@JAMADerm) April 19, 2023